Palbociclib

Curated

← predicts response to

PIK3CA E453GSNV

sensitivity

Curated

← predicts response to

PIK3CA E453DSNV

sensitivity

Curated

← predicts response to

PIK3CA E453ASNV

sensitivity

Curated

← predicts response to

PIK3CA E453QSNV

sensitivity

Curated

← predicts response to

PIK3CA E453KSNV

sensitivity

Curated

← predicts response to

PIK3CA M1043TSNV

sensitivity

Curated

← predicts response to

PIK3CA M1043ISNV

sensitivity

Curated

← predicts response to

PIK3CA M1043VSNV

sensitivity

Curated

← predicts response to

PIK3CA C420RSNV

sensitivity

Curated

← predicts response to

PIK3CA R88QSNV

sensitivity

Curated

← predicts response to

PIK3CA N345YSNV

sensitivity

Curated

← predicts response to

PIK3CA N345TSNV

sensitivity

Curated

← predicts response to

PIK3CA N345SSNV

sensitivity

Curated

← predicts response to

PIK3CA N345ISNV

sensitivity

Curated

← predicts response to

PIK3CA N345HSNV

sensitivity

Curated

← predicts response to

PIK3CA N345DSNV

sensitivity

Curated

← predicts response to

PIK3CA N345KSNV

sensitivity

Curated

← predicts response to

PIK3CA G1049DSNV

sensitivity

Curated

← predicts response to

PIK3CA G1049CSNV

sensitivity

Curated

← predicts response to

PIK3CA G118DSNV

sensitivity

Curated

← predicts response to

PIK3CA G106DSNV

sensitivity

Curated

← predicts response to

PIK3CA G106ASNV

sensitivity

Curated

← predicts response to

PIK3CA G106SSNV

sensitivity

Curated

← predicts response to

PIK3CA G1049ASNV

sensitivity

Curated

← predicts response to

PIK3CA G106RSNV

sensitivity

Curated

← predicts response to

PIK3CA G106VSNV

sensitivity

Curated

← predicts response to

PIK3CA G1049RSNV

sensitivity

Curated

← predicts response to

PIK3CA G1049SSNV

sensitivity

Curated

← predicts response to

PIK3CA Q546HSNV

sensitivity

Curated

← predicts response to

PIK3CA K111RSNV

sensitivity

Curated

← predicts response to

PIK3CA K111NSNV

sensitivity

Curated

← predicts response to

PIK3CA K111ESNV

sensitivity

Curated

← predicts response to

PIK3CA Q546LSNV

sensitivity

Curated

← predicts response to

PIK3CA Q546RSNV

sensitivity

Curated

← predicts response to

PIK3CA Q546PSNV

sensitivity

Curated

← predicts response to

PIK3CA Q546ESNV

sensitivity

Curated

← predicts response to

PIK3CA Q546KSNV

sensitivity

Curated

← predicts response to

PIK3CA E542VSNV

sensitivity

Curated

← predicts response to

PIK3CA E542RSNV

sensitivity

Curated

← predicts response to

PIK3CA E542GSNV

sensitivity

Curated

← predicts response to

PIK3CA E542DSNV

sensitivity

Curated

← predicts response to

PIK3CA E542ASNV

sensitivity

Curated

← predicts response to

PIK3CA E542QSNV

sensitivity

Curated

← predicts response to

PIK3CA E542KSNV

sensitivity

Curated

← predicts response to

PIK3CA E545RSNV

sensitivity

Curated

← predicts response to

PIK3CA E545LSNV

sensitivity

Curated

← predicts response to

PIK3CA E545DSNV

sensitivity

Curated

← predicts response to

PIK3CA E545VSNV

sensitivity

Curated

← predicts response to

PIK3CA E545GSNV

sensitivity

Curated

← predicts response to

PIK3CA E545ASNV

sensitivity

Curated

← predicts response to

PIK3CA E545QSNV

sensitivity

Curated

← predicts response to

PIK3CA E545KSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047TSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047QSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047PSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047NSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047ISNV

sensitivity

Curated

← predicts response to

PIK3CA H1047DSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047LSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047YSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047RSNV

sensitivity

Curated

← predicts response to

CDK4 Amplificationamplification

2 source records aggregated

sensitivity

Liposarcoma

Curated

← predicts response to

GNAS Mutationother

sensitivity

Pseudomyxoma Peritonei

Curated

← predicts response to

ESR1 Mutationother

resistance

Curated

← predicts response to

PIK3CA Mutationother

resistance

Curated

← predicts response to

RB1 Mutationother

resistance

Curated

← predicts response to

CDKN2A Lossdeletion_cna

sensitivity

Curated

← predicts response to

CDKN2A Mutationother

sensitivity

Curated

← predicts response to

RB1 Wildtypeother

sensitivity

Curated

← predicts response to

CCNE1 Underexpressionexpression

sensitivity

Curated

← predicts response to

ESR1 Overexpressionexpression

sensitivity

Curated

← predicts response to

CDKN2A Lossdeletion_cna

sensitivity

—

Curated

Cutaneous Melanoma,Dermatofibrosarcoma Protuberans,Ewing Sarcoma+2

← predicts response to

CDKN2A Lossdeletion_cna

5 source records aggregated

sensitivity

Curated

← predicts response to

CDK6 Overexpressionexpression

2 source records aggregated

sensitivity

—

Curated

Ewing Sarcoma,Renal Cell Carcinoma

← predicts response to

CDKN2B Lossdeletion_cna

2 source records aggregated

sensitivity

Curated

Glioblastoma,Malignant Breast Neoplasm

← predicts response to

RB1 Loss-of-function

2 source records aggregated

resistance

Curated

← predicts response to

CCND1 Overexpressionexpression

sensitivity

Mantle Cell Lymphoma

Curated

← predicts response to

CDK4 R24CSNV

sensitivity

Cutaneous Melanoma

Curated

← predicts response to

KRAS G12VSNV

sensitivity

Curated

← predicts response to

RB1 M695FS*26indel

resistance

—

Curated

← predicts response to

CCND1 Amplificationamplification

sensitivity

Curated

HER2-Positive Breast Carcinoma

← predicts response to

ERBB2 Amplificationamplification

sensitivity

Curated

Malignant Appendix Neoplasm

← predicts response to

GNAS Mutationother

sensitivity

Curated

← predicts response to

CCNE1 Amplificationamplification

resistance

—

Curated

← predicts response to

PIK3CA Mutationother

sensitivity

Curated

T Lymphoblastic Leukemia/Lymphoma

← predicts response to

CCND3 Lossdeletion_cna

sensitivity

Curated

← predicts response to

SMARCA4 Lossdeletion_cna

sensitivity

Curated

← predicts response to

CDK4 EXPRESSIONexpression

sensitivity

Sarcoma

Curated

Malignant Colorectal Neoplasm

← predicts response to

KRAS Mutationother

sensitivity

Curated

← predicts response to

FGFR1 Amplificationamplification

sensitivity

Curated

Palbociclib targets …TARGETS3 of 3
→ targets	CDK4	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	CCND1	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	CDK6	—	INHIBITOR	—	1	Curated	chembl	graph →

Palbociclib targets …TARGETS3 of 3

→ targets

CDK4

—

INHIBITOR

—

Curated

→ targets

CCND1

—

INHIBITOR

—

Curated

→ targets

CDK6

—

INHIBITOR

—

Curated

Palbociclib investigated for …INVESTIGATED_FOR15 of 54show all (up to 200)
→ investigated for	Malignant Breast Neoplasmcancer_family 8 source records aggregated	supports	A	Malignant Breast Neoplasm	8	Curated	civic	graph →
→ investigated for	Malignant Breast Neoplasmcancer_family 3 source records aggregated	supports	B	Malignant Breast Neoplasm	3	Curated	civic	graph →
→ investigated for	Liposarcomasubtype 2 source records aggregated	supports	B	Liposarcoma	2	Curated	civic	graph →
→ investigated for	Pseudomyxoma Peritoneisubtype	supports	B	Pseudomyxoma Peritonei	1	Curated	civic	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	supports	B	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Breast Neoplasmcancer_family	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
→ investigated for	Sarcomacancer_family	unknown	3	Sarcoma	1	Curated	chembl	graph →
→ investigated for	Squamous Cell Carcinomahistology	unknown	3	Squamous Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Malignant Breast Neoplasmcancer_family 4 source records aggregated	supports	D	Malignant Breast Neoplasm	4	Curated	civic	graph →
→ investigated for	Cutaneous Melanomacancer 2 source records aggregated	supports	D	Cutaneous Melanoma	2	Curated	civic	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype 2 source records aggregated	supports	D	Lung Non-Small Cell Carcinoma	2	Curated	civic	graph →
→ investigated for	Ewing Sarcomasubtype 2 source records aggregated	supports	D	Ewing Sarcoma	2	Curated	civic	graph →
→ investigated for	Renal Cell Carcinomasubtype 2 source records aggregated	supports	D	Renal Cell Carcinoma	2	Curated	civic	graph →
→ investigated for	Mantle Cell Lymphomahematologic_malignancy	supports	D	Mantle Cell Lymphoma	1	Curated	civic	graph →

Palbociclib investigated for …INVESTIGATED_FOR15 of 54show all (up to 200)

→ investigated for

Malignant Breast Neoplasmcancer_family

8 source records aggregated

supports

Curated

→ investigated for

Malignant Breast Neoplasmcancer_family

3 source records aggregated

supports

Curated

→ investigated for

Liposarcomasubtype

2 source records aggregated

supports

Liposarcoma

Curated

→ investigated for

Pseudomyxoma Peritoneisubtype

supports

Pseudomyxoma Peritonei

Curated

→ investigated for

Lung Non-Small Cell Carcinomasubtype

supports

Curated

→ investigated for

Neoplasmcancer_family

unknown

Neoplasm

Curated

→ investigated for

Breast Neoplasmcancer_family

unknown

Curated

→ investigated for

Sarcomacancer_family

unknown

Sarcoma

Curated

→ investigated for

Squamous Cell Carcinomahistology

unknown

Squamous Cell Carcinoma

Curated

→ investigated for

Malignant Breast Neoplasmcancer_family

4 source records aggregated

supports

Curated

→ investigated for

Cutaneous Melanomacancer

2 source records aggregated

supports

Cutaneous Melanoma

Curated

→ investigated for

Lung Non-Small Cell Carcinomasubtype

2 source records aggregated

supports

Curated

→ investigated for

Ewing Sarcomasubtype

2 source records aggregated

supports

Ewing Sarcoma

Curated

→ investigated for

Renal Cell Carcinomasubtype

2 source records aggregated

supports

Renal Cell Carcinoma

Curated

→ investigated for

Mantle Cell Lymphomahematologic_malignancy

supports

Mantle Cell Lymphoma

Curated

Palbociclib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 187show all (up to 200)
→ investigated in trials for	Malignant Breast Neoplasmcancer_family 121 trials (42 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	121	Observed	clinicaltrials	graph →
→ investigated in trials for	Breast Neoplasmcancer_family 32 trials (12 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Breast Neoplasm	32	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 18 trials (12 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Breast Carcinoma 15 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Breast Carcinoma	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Solid Neoplasm 14 trials (8 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Solid Neoplasm	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 8 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Ovarian Neoplasm 8 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Ovarian Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Solid Neoplasm 6 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Solid Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	HER2-Positive Breast Carcinoma 6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	HER2-Positive Breast Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Pancreatic Neoplasm 6 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Pancreatic Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Melanoma 6 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Melanoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Carcinoma 6 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Lymphoblastic Leukemia 5 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Lymphoblastic Leukemia	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colorectal Neoplasm 5 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	5	Observed	clinicaltrials	graph →

Palbociclib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 187show all (up to 200)

→ investigated in trials for

Malignant Breast Neoplasmcancer_family

121 trials (42 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

121

Observed

→ investigated in trials for

Breast Neoplasmcancer_family

32 trials (12 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

Solid Neoplasm

18 trials (12 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Solid Neoplasm

Observed

→ investigated in trials for

Breast Carcinoma

15 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Breast Carcinoma

Observed

→ investigated in trials for

Malignant Solid Neoplasm

14 trials (8 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Solid Neoplasm

Observed

→ investigated in trials for

Malignant Neoplasm

8 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Neoplasm

Observed

Malignant Ovarian Neoplasm

→ investigated in trials for

8 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Ovarian Neoplasm

Observed

→ investigated in trials for

Adult Solid Neoplasm

6 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Adult Solid Neoplasm

Observed

HER2-Positive Breast Carcinoma

→ investigated in trials for

6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

HER2-Positive Breast Carcinoma

Observed

→ investigated in trials for

Lung Non-Small Cell Carcinomasubtype

6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

Malignant Pancreatic Neoplasm

→ investigated in trials for

6 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Pancreatic Neoplasm

Observed

→ investigated in trials for

Melanoma

6 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Melanoma

Observed

→ investigated in trials for

Ovarian Carcinoma

6 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Ovarian Carcinoma

Observed

Acute Lymphoblastic Leukemia

→ investigated in trials for

5 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Acute Lymphoblastic Leukemia

Observed

Malignant Colorectal Neoplasm

→ investigated in trials for

5 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Colorectal Neoplasm

Observed

Palbociclib studied in …STUDIED_INderived10 of 283show all (up to 200)
→ studied in	NCT04711252Phase 3 · active not recruiting A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease · 283 trials list this drug (108 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · 283 trials list this drug (108 active)	—	—	Malignant Solid Neoplasm,Primary Peritoneal Carcinoma,Malignant Female Reproductive System Neoplasm+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT05867251Phase 1/Phase 2 · recruiting Study of AVZO-021 in Patients With Advanced Solid Tumors · 283 trials list this drug (108 active)	—	—	Solid Neoplasm,Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT07492641Phase 3 · recruiting BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease · 283 trials list this drug (108 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT01723774Phase 2 · active not recruiting PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer · 283 trials list this drug (108 active)	—	—	Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06377852Phase 3 · recruiting The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study · 283 trials list this drug (108 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03573648Phase 2 · active not recruiting Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer · 283 trials list this drug (108 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04224272Phase 2 · completed Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant · 283 trials list this drug (108 active)	—	—	Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05384119Phase 1 · terminated Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer · 283 trials list this drug (108 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04964934Phase 3 · active not recruiting Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) · 283 trials list this drug (108 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →

Palbociclib studied in …STUDIED_INderived10 of 283show all (up to 200)

→ studied in

NCT04711252Phase 3 · active not recruiting

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease · 283 trials list this drug (108 active)

—

not mapped

Observed

Malignant Solid Neoplasm,Primary Peritoneal Carcinoma,Malignant Female Reproductive System Neoplasm+2

→ studied in

NCT05564377Phase 2 · recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · 283 trials list this drug (108 active)

—

Observed

Solid Neoplasm,Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma+1

→ studied in

NCT05867251Phase 1/Phase 2 · recruiting

Study of AVZO-021 in Patients With Advanced Solid Tumors · 283 trials list this drug (108 active)

—

Observed

→ studied in

NCT07492641Phase 3 · recruiting

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease · 283 trials list this drug (108 active)

—

not mapped

Observed

→ studied in

NCT01723774Phase 2 · active not recruiting

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer · 283 trials list this drug (108 active)

—

Observed

→ studied in

NCT06377852Phase 3 · recruiting

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study · 283 trials list this drug (108 active)

—

Observed

→ studied in

NCT03573648Phase 2 · active not recruiting

Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer · 283 trials list this drug (108 active)

—

Observed

→ studied in

NCT04224272Phase 2 · completed

Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant · 283 trials list this drug (108 active)

—

Observed

→ studied in

NCT05384119Phase 1 · terminated

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer · 283 trials list this drug (108 active)

—

Observed

→ studied in

NCT04964934Phase 3 · active not recruiting

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) · 283 trials list this drug (108 active)

—

not mapped

Observed